CS Diagnostics Corp. Files 8-K

TL;DR

CS DIAGNOSTICS CORP. filed an 8-K on 10/31/25. Nothing major, just standard reporting.

AI Summary

CS Diagnostics Corp. filed an 8-K on October 31, 2025, reporting other events and financial statements as of October 30, 2025. The company, formerly known as Flashzero Corp., Childrens Internet Inc., and DWC Installations, is incorporated in Wyoming and operates in the specialty cleaning, polishing, and sanitation preparations industry.

Why It Matters

This filing indicates CS Diagnostics Corp. is providing updates on its corporate activities and financial status, which is important for investors to monitor the company's ongoing operations and compliance.

Risk Assessment

Risk Level: low — This filing is a routine 8-K for other events and financial statements, with no immediate indication of significant financial distress or major corporate changes.

Key Players & Entities

• CS DIAGNOSTICS CORP. (company) — Registrant
• Flashzero Corp. (company) — Former Company Name
• Childrens Internet Inc (company) — Former Company Name
• DWC Installations (company) — Former Company Name
• October 30, 2025 (date) — Date of earliest event reported
• October 31, 2025 (date) — Filing Date

FAQ

Key Financial Figures

• $0.00001 — f the Company's Common Stock, par value $0.00001 per share (the "Common Shares"). The c

Filing Documents

• i10312518k.htm (8-K) — 24KB
• ex99_1.htm (EX-99.1) — 16KB
• cscorp_logo.jpg (GRAPHIC) — 14KB
• 0001214659-25-015660.txt ( ) — 241KB
• csdx-20251030.xsd (EX-101.SCH) — 3KB
• csdx-20251030_lab.xml (EX-101.LAB) — 33KB
• csdx-20251030_pre.xml (EX-101.PRE) — 22KB
• i10312518k_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events On October 30, 2025, CS Diagnostics Corp. (the "Company" or "CSDX") completed the conversion of all outstanding shares of its Series B Preferred Stock (the "Preferred B Shares") held by its affiliate companies, CS Interpharm General Trading Co. LLC ("CS Interpharm") and CS Diagnostics Pharma GmbH ("CS Diagnostics Pharma"), into shares of the Company's Common Stock, par value $0.00001 per share (the "Common Shares"). The conversion was affected pursuant to the terms of the Certificate of Designation governing the Preferred B Shares and resulted in the issuance of an aggregate 112,652,000 Common Shares. The conversion aligns the capital structures of the Company and its affiliates in preparation for consolidated financial reporting for the fiscal year ending December 31, 2025. The Common Shares issued upon conversion were not registered under the Securities Act of 1933, as amended (the "Securities Act"), and were issued in reliance on the exemption from registration provided by Section 3(a)(9) thereof, as the exchange was made exclusively with existing security holders, no commission or other remuneration was paid or given directly or indirectly for soliciting such exchange, and the affiliates are not issuers, underwriters, or dealers. Alternatively, to the extent applicable, the transaction also qualifies for exemption under Section 4(a)(2) as a transaction not involving a public offering. This strategic conversion simplifies the Company's equity capitalization, enhances transparency, and strengthens alignment among CSDX and its affiliated entities. Following the conversion, the affiliates now hold their ownership interests directly through Common Shares, fostering greater alignment with all shareholders and supporting long-term value creation and financial consolidation. Notably, the consolidation will integrate the income and revenue streams from CS Interpharm and CS Diagnostics Pharma directly into CSDX's financial statements, providing

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits Exhibit No. Exhibit Description 99.1 Press Release dated October 31, 2025, announcing the conversion of Preferred B Shares to Common Stock.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 31, 2025 CS Diagnostics Corp. By: /s/Mohammad EsSayed Mohammad EsSayed Group CFO, VP

View Full Filing

View this 8-K filing on SEC EDGAR